The last twelve months haven’t been particularly good in terms of market performance for Alnylam Pharmaceuticals (ALNY),
and that hasn’t really changed much over the last three months either,
as the shares continue to lag biotech indices. With top-line Phase III
givosiran data looking good on efficacy but leaving some questions as to
safety, the ENVISION study hasn’t been much of a catalyst and that may
be the case for a little while longer. I do believe these shares remain
undervalued, though, and offer some attractive long-term upside.
Click here for more:
Alnylam Is A Step Closer To Its Second Approved Drug
No comments:
Post a Comment